Prof Andrea De Censi speaks to ecancer at SABCS 2018 about the results of the phase III TAM-01 clinical trial, where low-dose tamoxifen was found to be safe and effective in reducing recurrence and new breast disease for patients with DCIS, LCIS and ADH.
He explains they found that a much lower dose of tamoxifen resulted in around the same reduction of recurrence than past results with much higher doses, with less side effects.
Prof De Censi concludes by saying the results of this study this opens the doors for a primary prevention trial for healthy at risk women.
Watch his press conference here.
Read more about this work here.